We are developing “single enzyme activity-based liquid biopsy”
for early detection of diseases and drug development support.
Pre-Series A Funding to Accelerate R&D of Cancer Early Detection Blood Test
Kobe University and Cosomil explore novel biomarkers for pancreatic cancer
Cosomil, Inc. Earns JST President’s Award at Awards for Academic Startups 2023
Osaka Metropolitan University and Cosomil collaborate to advance detection of hepatobiliary pancreatic cancers
We are developing high-precision liquid-based diagnostic technology using "single enzyme activity-based protein profiling (SEAP),"
to evaluate the activity of enzymes in the blood molecule at single protein level.
Our business focuses on 2 main areas: early disease diagnosis and support for drug development.
For example, by utilizing our "single enzyme activity-based protein profiling (SEAP)" technology, pancreatic cancer may be detected in its early stage.
We will contribute to future growth of healthcare
by applying fluorescent enzyme substrates and microdevices.